托法替布在幼年特发性关节炎中的应用研究进展  

Research progress in the application of tofacitinib for juvenile idiopathic arthritis

作　　者：周敬强 林穆娜 张亚萍 韩旭 ZHOU Jing-qiang;LIN Mu-na;ZHANG Ya-ping;HAN Xu(Department of Pharmacy,Huainan Maternal and Child Health Care Hospital,Huainan Anhui 232000;Department of Pharmacy,Quanjiao People’s Hospital,Chuzhou Anhui 239500)

机构地区：[1]淮南市妇幼保健院药剂科,安徽淮南232000 [2]全椒县人民医院药剂科,安徽滁州239500

出　　处：《中南药学》2025年第1期184-188,共5页Central South Pharmacy

摘　　要：幼年特发性关节炎是一种病因不明的异质性慢性关节炎,好发于16岁以下的儿童,持续至少6周。托法替布是一种新型的口服小分子Janus激酶(主要是JAK1和亚型JAK3)选择靶向性抑制剂,具有免疫调节和抗炎特性。2020年,托法替布被美国食品药品监督管理局(FDA)批准用于2岁及以上儿童的活动性多关节型幼年特发性关节炎,由于其在儿童中使用的证据有限,使得国内关于托法替布治疗幼年特发性关节炎的报道较少。本文主要从托法替布治疗幼年特发性关节炎的作用机制、药动学特征、临床应用和安全性4个方面总结其相关研究进展,以期为临床应用带来参考。Juvenile idiopathic arthritis is a heterogeneous chronic arthritis of unknown etiology that tends to occur in children under 16 years of age and last for at least 6 weeks.Tofacitinib is a novel oral small-molecule selective targeted inhibitor of Janus kinases(primarily JAK1 and subtype JAK3)with immunomodulatory and anti-inflammatory properties.In 2020,tofacitinib was approved by the U.S.Food and Drug Administration for treating active multiarticular juvenile idiopathic arthritis in children 2 years of age and older.Limited evidence of its use in children resulted in very few reports of tofacitinib for the treatment of juvenile idiopathic arthritis in China.This paper summarized the research progress of tofacitinib in the treatment of juvenile idiopathic arthritis from mechanism of action,pharmacokinetic characteristicsclinical,application and safety to provide reference for its clinical application.

关 键 词：幼年特发性关节炎 托法替布 作用机制 药动学特征 临床应用 安全性 

分 类 号：R725.9[医药卫生—儿科]